Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Boston Scientific ( (BSX) ) has issued an update.
On January 14, 2026, Boston Scientific entered into a definitive agreement to acquire Penumbra, Inc. via a merger in which Penumbra will become a wholly owned subsidiary, with Penumbra shareholders able to elect either cash of $374 per share or 3.8721 Boston Scientific shares per Penumbra share, subject to proration that targets roughly 73% cash and 27% stock. The deal includes detailed treatment of Penumbra stock options and restricted stock units, customary closing conditions such as antitrust and other regulatory approvals, Penumbra shareholder approval, stock exchange listing of new Boston Scientific shares, and mutual covenants restricting Penumbra from soliciting competing bids except under a fiduciary out, alongside substantial reverse and standard termination fees that underscore both parties’ commitment and highlight regulatory and competitive risks for investors and other stakeholders.
The most recent analyst rating on (BSX) stock is a Buy with a $121.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.
Spark’s Take on BSX Stock
According to Spark, TipRanks’ AI Analyst, BSX is a Outperform.
Boston Scientific’s overall stock score is driven by strong financial performance and positive earnings call outcomes. While the technical analysis and valuation present some concerns, the company’s robust growth trajectory and raised guidance support a favorable outlook.
To see Spark’s full report on BSX stock, click here.
More about Boston Scientific
Boston Scientific Corporation is a global medical technology company that develops and manufactures devices for a range of interventional medical specialties, including cardiovascular, neurological and other minimally invasive procedures. The company focuses on expanding its portfolio through strategic acquisitions to strengthen its position in high-growth therapeutic areas and broaden its presence in hospital and procedural settings worldwide.
Average Trading Volume: 8,832,848
Technical Sentiment Signal: Buy
Current Market Cap: $139B
Find detailed analytics on BSX stock on TipRanks’ Stock Analysis page.